Fagron NV (EBR:FAGR)
Market Cap | 1.51B |
Revenue (ttm) | 918.75M |
Net Income (ttm) | 85.69M |
Shares Out | 73.09M |
EPS (ttm) | 1.17 |
PE Ratio | 17.61 |
Forward PE | 15.47 |
Dividend | 0.35 (1.69%) |
Ex-Dividend Date | May 19, 2025 |
Volume | 41,822 |
Average Volume | 76,667 |
Open | 20.65 |
Previous Close | 20.65 |
Day's Range | 20.55 - 20.75 |
52-Week Range | 15.14 - 23.50 |
Beta | 0.25 |
RSI | 29.05 |
Earnings Date | Jul 31, 2025 |
About Fagron NV
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, patients, and worldwide. It operates through three segments: Essentials, Brands, and Compounding Services. The company products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders, such as vitiligo; Pentravan uses for avoiding first-pass metabolism and preventing gastrointest... [Read more]
Full Company ProfileFinancial Performance
In 2024, Fagron NV's revenue was 871.96 million, an increase of 14.28% compared to the previous year's 762.99 million. Earnings were 80.55 million, an increase of 14.18%.
Financial StatementsNews

Fagron increases share capital through exercise subscription rights
Regulated informationNazareth (Belgium)/Rotterdam (The Netherlands), 6 June 2025 – 7PM CET Fagron increases share capital through exercise subscription rights Fagron announces that as a result of the ...
Fagron: Recent Capital Markets Day Confirms Upside Potential

Record first-quarter revenue of €239 million, reflecting 14% topline growth
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 April 2025 – 7:00 AM CET Record first-quarter revenue of €239 million, reflecting 14% topline growth Fagron...

Fagron: FDA Warning Letter Creates New Entry Opportunity
Fagron: FDA Warning Letter Creates New Entry Opportunity

Fagron reports outstanding third quarter 2024 performance with 12.1% revenue growth and reaffirms full-year outlook
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 10 October 2024 – 7:00 AM CET Fagron reports outstanding third quarter 2024 performance with 12.1% revenue gro...

Record revenue of €209 million in first quarter reflecting 15% topline growth
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 11 April 2024 – 7:00 AM CET Record revenue of €209 million in first quarter reflecting 15% topline growth Fagr...

Continued strong third quarter performance with 11% topline growth to €191 million
Regulated information - inside informationNazareth (Belgium)/Rotterdam (The Netherlands), 12 October 2023 – 7:00 AM CET Continued strong third quarter performance with 11% topline growth to €191 milli...

Fagron NV (ARSUF) Q2 2023 Earnings Call Transcript
Fagron NV (OTC:ARSUF) Q2 2023 Earnings Conference Call August 3, 2023 3:30 AM ET Company Participants Karen Berg - Investor Relations Rafael Padilla - Chief Executive Officer Karin de Jong - Chief Fin...